This review provides Professor Coyle’s treatment principles and perspective on how early to treat MS and the importance of minimising brain atrophy. Dr Coyle discusses strategies for selecting disease modifying treatment (DMT), weighing up benefits and risks of MS therapies and evaluating the efficacy of DMTs across trials. She also emphasises the importance of ongoing MRI surveillance, monitoring tolerability and safety, and switching agents due to unacceptable disease breakthrough.
Please login below to download this issue (PDF)